Sanoma Corporation, Stock Exchange Release, 8 September 2026 at 4:15 p.m. EET Sanoma’s financial reporting in 2027 In 2027, Sanoma Corporation will publish financial information as follows: Full-Year Result 2026                                               Thursday, 18 FebruaryInterim Report 1 January–31 March 2027                Wednesday, 28 AprilHalf-Year Report 1 January–30 June 2027               Wednesday, 28 JulyInterim Report 1 January–30 September 2027         Friday, 29 October Sanoma practices a silent period of 30 days prior to publishing financial information. Sanoma’s Financial Statements and Directors’ Report for 2026 will be published during week 10, which starts on 8 March 2027. Sanoma Corporation’s Annual General Meeting (AGM) 2027 is planned to be held on Wednesday, 28 April 2027 in Helsinki. The Board of Directors...

DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for critical materials production, today hosts its inaugural Capital Markets Day in London. Management will outline the Company’s strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and will provide an overview of the building blocks supporting the Company’s long-term growth potential. Over the past 12 months, the Company has moved from development into early commercialization across several of its businesses. At today’s event, management intends to provide a summary of what has been achieved to date, target milestones for the next 12 months, and how the complementary businesses...

BOSTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST) today announced the completion of a sale of substantially all remaining inventory associated with its Vytex business as the Company continues its strategic repositioning following its acquisition of the R3ALM Financial Ecosystem. Vystar CEO Jamie Rotman stated, “I have completed a sale of substantially all remaining Vytex inventory, consisting of 1,395 individual pieces, including toppers, beds, pillows and covers. All of the inventory has now left our warehouse.” The transaction represents another step in Vystar’s efforts to streamline its legacy operations and concentrate resources on the development of the R3ALM ecosystem. Vystar’s Strategic Focus on R3ALM Vystar is increasingly focused on R3ALM and its potential to participate in the rapidly developing...

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and China during September 2026. These speaking engagements position Akari’s proprietary PH1 ADC payload technology in front of leading global pharmaceutical...

GreetEat Corporation Announces 2026–2027 Corporate Growth Roadmap Focused on PCAOB Audit, Strategic Capital, ChefKart Expansion, Acquisitions and Nasdaq Uplisting RENO, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) — GreetEat Corporation (OTC: GEAT) (“GreetEat” or the “Company”) today announced its strategic corporate roadmap for 2026 and 2027, focused on strengthening the Company’s public-market infrastructure, accessing growth capital, accelerating the development of ChefKart, pursuing strategic acquisitions and positioning GreetEat for a future uplisting to Nasdaq. Management believes GreetEat is entering an important stage of its corporate development and intends to focus on building a scalable, technology-enabled operating platform capable of supporting multiple businesses and future growth opportunities. 2026–2027 STRATEGIC ROADMAP 1....

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for lowering the cost of production of CAR-T therapies MIRAMAR, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ:...